Topic Hub
7 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 7 of 7 clinical reviews.
Evolocumab (Repatha) carries an FDA-approved indication for reducing cardiovascular events in established ASCVD. Learn the dosing protocol, FOURIER trial evidence, guideline recommendations, and when prescribing may extend beyond the label.
Read clinical reviewA clinical evidence summary of evolocumab (Repatha) for secondary prevention in atherosclerotic cardiovascular disease (ASCVD), including FOURIER trial data, guideline recommendations, dosing, and safety.
Read clinical reviewEvolocumab (Repatha) is FDA-approved for heterozygous and homozygous familial hypercholesterolemia. Learn about dosing, monitoring protocols, trial data from FOURIER and RUTHERFORD-2, and guideline recommendations.
Read clinical reviewA clinician-reviewed guide to evolocumab (Repatha) in ASCVD secondary prevention: FDA-approved vs. Off-label context, FOURIER trial data, dosing protocols, LDL-C targets, and required monitoring.
Read clinical reviewA physician-reviewed evidence summary covering evolocumab (Repatha) for familial hypercholesterolemia, including FDA-approved indications, off-label use, trial data, dosing, and guideline recommendations.
Read clinical reviewA clinical review of evolocumab (Repatha) for familial hypercholesterolemia, including FDA approval status, off-label contexts, dosing protocols, trial evidence, and physician guidance.
Read clinical reviewEvolocumab (Repatha) is FDA-approved for adults with primary hyperlipidemia and established ASCVD, but its use in pediatric FH and certain FH subtypes is technically off-label. This guide covers the evidence base, GRADE ratings, dosing, risks, and how clinicians weigh the trade-offs.
Read clinical review